Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer

In patients with advanced urothelial cancer (UC), a combination of cisplatin (CDDP) and gemcitabine (GEM) is the most commonly used first-line systematic chemotherapy regimen. Although no standard regime for the treatment of CDDP-resistant UC has been established, GEM-based regimens are frequently u...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Lett
Egile Nagusiak: Miyata, Yasuyoshi, Mitsunari, Kensuke, Akihiro, Asai, Watanabe, Shin-Ichi, Matsuo, Tomohiro, Ohba, Kojiro, Sakai, Hideki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2017
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351343/
https://ncbi.nlm.nih.gov/pubmed/28356963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.5484
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak